Predicting Delirium in Older Non-intensive Care Unit Inpatients: Development and Validation of the DELIrium RisK Tool (DELIKT)
Overview
Pharmacy
Authors
Affiliations
Background: Effective delirium prevention could benefit from automatic risk stratification of older inpatients using routinely collected clinical data.
Aim: Primary aim was to develop and validate a delirium prediction model (DELIKT) suitable for implementation in hospitals. Secondary aim was to select an anticholinergic burden scale as a predictor.
Method: We used one cohort for model development and another for validation with electronically available data collected within the first 24 h of admission. Included were patients aged ≥ 65, hospitalised ≥ 48 h with no stay > 24 h in an intensive care unit. Predictors, such as administrative and laboratory variables or an anticholinergic burden scale, were selected using a combination of feature selection filter method and forward/backward selection. The final model was based on logistic regression and the DELIKT was derived from the β-coefficients. We report the following performance measures: area under the curve, sensitivity, specificity and odds ratio.
Results: Both cohorts were similar and included over 10,000 patients each (mean age 77.6 ± 7.6 years) with 11% experiencing delirium. The model included nine variables: age, medical department, dementia, hemi-/paraplegia, catheterisation, potassium, creatinine, polypharmacy and the anticholinergic burden measured with the Clinician-rated Anticholinergic Scale (CrAS). The external validation yielded an AUC of 0.795. With a cut-off at 20 points in the DELIKT, we received a sensitivity of 79.7%, specificity of 62.3% and an odds ratio of 5.9 (95% CI 5.2, 6.7).
Conclusion: The DELIKT is a potentially automatic tool with predictors from standard care including the CrAS to identify patients at high risk for delirium.
Morganti W, Custodero C, Veronese N, Topinkova E, Michalkova H, Polidori M Eur Geriatr Med. 2024; 15(4):961-969.
PMID: 38878221 PMC: 11377617. DOI: 10.1007/s41999-024-00987-y.
Mohmaed Ali M, Kalkman G, Wijers C, Fleuren H, Kramers C, de Wit H Int J Clin Pharm. 2023; 45(5):1128-1135.
PMID: 37713029 DOI: 10.1007/s11096-023-01641-6.